Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
globenewswire.comAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studiesglobenewswire.comMay 26
globenewswire.comAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Modelsglobenewswire.comMay 18
prnewswire.comValion Bio Appoints Melinda Lackey as General Counselprnewswire.comMay 4